Lung cancer continues to be the leading cause of cancer mortality worldwide^[@R1]^. Although tobacco smoking is the main risk factor, the heritability of lung cancer has been estimated at 18%^[@R2]^. Genome-wide association studies (GWAS) have previously identified several lung cancer susceptibility loci including *CHRNA3/5, TERT, HLA, BRCA2, CHEK2*^[@R3],[@R4]^, but most of its heritability remains unexplained. With the goal of conducting a comprehensive characterization of common lung cancer genetic susceptibility loci, we undertook additional genotyping of lung cancer cases and controls using the OncoArray^[@R5]^ genotyping platform, which queried 517,482 SNPs chosen for fine mapping of susceptibility to common cancers as well as for *de novo* discovery ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}, and Online Methods). All participants gave an informed consent, and each study obtained local ethics committee approval. After quality control filters (Online Methods), a total of 14,803 cases and 12,262 controls of European ancestry were retained and underwent imputation techniques to infer additional genotypes for genetic variants included in the 1000 Genomes Project data (Online Methods). Logistic regression was then used to assess the association between variants (n=10,439,017 SNPs) and lung cancer risk, as well as by predominant histological types and by smoking behavior (Online Methods). Fixed-effects models (Online Methods) were used to combine the OncoArray results with previously published lung cancer GWAS^[@R3],[@R4],[@R6]^, allowing for analysis of 29,266 patients and 56,450 controls of European descent ([Table 1](#T1){ref-type="table"}). There were no signs of genomic inflation overall or for any subtypes ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) indicating little evidence for confounding by cryptic population structure (Online Methods). All findings with a P-value less than 1×10^−5^ are reported in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. As shown in [Figure 1](#F1){ref-type="fig"}, the genetic architecture of lung cancer varies markedly among histological subtypes, with striking differences between lung adenocarcinoma and squamous cell carcinoma. Manhattan plots for small cell carcinoma (SCLC), ever and never smoking are displayed in [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}. The array heritability estimates were comparable among histological subsets, but squamous cell carcinoma appeared to share more genetic architecture with small cell carcinoma (SCLC) than with adenocarcinoma ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

[Table 2](#T2){ref-type="table"} presents summary results of all loci with sentinel variants (defined as the variant with the lowest P-value at each locus) that reached genome-wide significance (P-value \< 5×10^−8^) for lung cancer overall and by histological subtypes. Sentinel variants stratified by new and previous genotyping and additional statistical significance assessed based on the number of effective tests, Approximate Bayes Factors, and Bayesian False Discovery Probability are presented in [Supplementary Tables 4](#SD1){ref-type="supplementary-material"} and [5](#SD1){ref-type="supplementary-material"}, respectively. Repeat genotyping of 12% of the OncoArray genotyped samples confirmed the fidelity of the genotyping or imputation for the risk loci, and showed excellent concordance of imputation for SNPs with MAF\>0.05 (Online Methods, [Supplementary note](#SD1){ref-type="supplementary-material"}). Among the 18 loci that reached GWAS significance, 10 had not reached significance in a genome-wide scan ([Figure 1](#F1){ref-type="fig"}). Of these, four novel loci were associated with lung cancer overall, and six with adenocarcinoma.

To decipher the association between these 18 loci and lung cancer risk, we further investigated their association with gene expression level in normal lung tissues (n=1,425) ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}, [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}), genomic annotations ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}), smoking propensity (cigarettes smoked per day (n=91,046) and Fagerström Test for Nicotine Dependence metrics (n=17,074)) ([Table 2](#T2){ref-type="table"}). Previous studies have shown shared risk for lung cancer and COPD through inflammation and ROS pathways^[@R7]^; therefore, we also assessed the association between sentinel SNPs and reduced lung capacity through spirometry measurements (forced expiratory volume in 1 second \[FEV1\], forced vital capacity \[FVC\], n =30,199) ([Table 2](#T2){ref-type="table"} and Online Methods).

Variants at 4 novel loci (1p31.1, 6q27, 8p21, 15q21.1) were associated with lung cancer risk overall, with little evidence for heterogeneity among subtypes ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). The 1p31.1 locus, recently identified in a pathway-based analysis of the TRICL data^[@R8]^, represented by rs71658797 (Odds Ratio \[OR\]=1.14, 95% Confidence Interval \[CI\] 1.09--1.18, P-value=3.25 × 10^−11^), is located near *FUBP1/DNAJB4* ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). At 6q27, rs6920364 was associated with lung cancer risk with an OR of 1.07 (95% CI 1.04--1.09, P-value=2.9×10^−8^) with little heterogeneity found by smoking status ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). This locus is predicted to regulate *RNASET2* ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}, [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). We identified rs6920364 as a lung cis-eQTL for *RNASET2*, an extracellular ribonuclease, in all five cohorts tested ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}), with increased lung cancer risk correlating with increased *RNASET2* expression ([Figure 2](#F2){ref-type="fig"}). Variants correlated with rs6920364 (r^2^\>0.88) have been noted in GWAS of Crohn's disease and inflammatory bowel disease^[@R9]--[@R13]^.

The 8p21 locus has been suggested as a lung cancer susceptibility locus by pathway analysis^[@R14]^ and now confirmed at GWAS significance level. It is a complex locus represented by sentinel variant rs11780471 associated with lung cancer (OR=0.87, 95% CI 0.83--0.91, P-value=1.69×10^−8^) ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}), but this region contained additional uncorrelated variants (pairwise r^2^\< 0.10) associated with lung cancer ([Supplementary Table 8](#SD1){ref-type="supplementary-material"}). Multivariate analysis was consistent with multiple susceptibility alleles at this locus ([Supplementary Table 8](#SD1){ref-type="supplementary-material"}). In contrast to lung tissue ([Figure 3A](#F3){ref-type="fig"}, [Supplementary Table 6](#SD1){ref-type="supplementary-material"}, [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}), we noted that the alleles associated with lung cancer tended to be associated with cerebellum expression of *CHRNA2*, a member of the cholinergic nicotinic receptor ([Figure 3B](#F3){ref-type="fig"}). The *CHRNA2* rs11780471 cis-eQTL effect in the brain was limited to the cerebellum ([Figure 3C](#F3){ref-type="fig"}), a region not traditionally linked with addictive behavior, but where an emerging role is suggested^[@R15]^. We therefore investigated rs11780471 in the context of smoking behavior ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). Unlike the well-described 15q25.1 (rs55781567) *CHRNA5* locus ([Table 2](#T2){ref-type="table"}), rs11780471 was not associated with number of cigarettes smoked per day or the FTND metrics ([Figure 3D](#F3){ref-type="fig"}). Nevertheless, lung cancer risk allele carriers of rs11780471 tended to be smokers and initiated smoking at earlier ages ([Figure 3D](#F3){ref-type="fig"}), implying that this variant's association with lung cancer could potentially be mediated via influencing aspects of smoking behavior. Another potentially relevant gene in this region is *EPHX2*, a xenobiotic metabolism gene. Although the sentinel variant is not an eQTL for *EPHX2* in lung tissues, other associated variants in the region are (e.g. rs146729428, p-value of 1.77×10^−7^ ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) and 5 × 10^−4^ for lung cancer risk and eQTL, respectively). A potential synergistic role of both *EPHX2* and *CHRNA2* on lung cancer etiology cannot be excluded.

The genetic locus at 15q21 (rs66759488) was shown to be associated with lung cancer (OR=1.07, 95% CI 1.04--1.10, p=2.83×10^−8^) overall and across lung cancer histologies ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). Genomic annotation suggests that genetic variants correlated with rs66759488 may influence the *SEMA6D* gene ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}), but there was no clear eQTL effect ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}), and this variant did not appear to have a major influence on smoking propensity or lung function ([Table 2](#T2){ref-type="table"}).

For specific lung cancer histology subtypes, we identified 6 novel loci associated with lung adenocarcinoma (15q21, 8p12, 10q24, 20q13.33, 11q23.3 and 9p21.3) ([Table 2](#T2){ref-type="table"}). The locus at 15q21 (rs77468143, OR=0.86, 95% CI 0.82--0.89, p=1.15×10^−16^) is predicted to target *SECISBP2L* ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}), and expression analysis indicated rs77468143 to be a cis-eQTL for *SECISBP2L* in lung tissue in all eQTL cohorts tested ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). The genetic risk allele appears to correlate with decreased expression levels of *SECISBP2L* ([Figure 2](#F2){ref-type="fig"}, [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}), an observation that is consistent with *SECISBP2L* being down regulated in lung cancers^[@R16]^. rs77468143 was nominally associated with lung function ([Table 2](#T2){ref-type="table"}), potentially implicating inflammation of lung as part of the mechanism at this locus.

At 8p12, expression analysis indicated that the alleles associated with lung adenocarcinoma (represented by the sentinel variant rs4236709 ([Table 2](#T2){ref-type="table"})), also appear to be a lung cis-eQTL for the *NRG1* gene ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}, [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). This region also contains putative regulatory regions ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). Somatic translocations of *NRG1* are infrequently observed in lung adenocarcinomas^[@R17]^. While somatic translocations at 8p12 generally take place in never smokers and are linked with ectopic activation of NRG1, rs4236709 was associated with lung cancer in both ever and never smokers ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}) and its genetic risk correlated with decreased *NRG1* expression ([Figure 2](#F2){ref-type="fig"}). Interestingly, 6q22.1 variants located near *ROS1*, another gene somatically translocated in lung adenocarcinoma and for which nearby germline variants were associated with never smoking lung adenocarcinoma in Asian women^[@R18]^, were associated with lung adenocarcinoma at borderline genome wide significance (rs9387479; OR=0.92, 95% CI 0.89--0.95, p=6.57×10^−8^) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Three of the sentinel variants associated with lung adenocarcinoma are located near genes related to telomere regulation; rs7902587 (10q24) and rs41309931 (20q13.33) near *OBFC1* and *RTEL1*, respectively, and rs2853677 near *TERT* as previously noted^[@R19],[@R20]^. The variants at 10q24 associated with lung adenocarcinoma also appear to be associated with telomere length ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}). By contrast, and consistent with observations with 20q13.33 variants associated with glioma^[@R21]^, the variants associated with telomere length at 20q13.33 were not necessarily those associated with lung adenocarcinoma ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}). Nevertheless, more generally the variants associated by GWAS with longer telomere length^[@R22]^ appear linked with risk of lung adenocarcinoma^[@R23]^ and glioma^[@R21],[@R24]^, a finding consistent with our expanded analysis here ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}).

We additionally identified a complex locus at 11q23.3. The sentinel variant rs1056562 (OR=1.11, 95% CI 1.07--1.14, p=2.7×10^−10^) is more prominently associated with lung adenocarcinoma ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). rs1056562 was correlated with expression of two genes at this locus, *AMICA1* and *MPZL3* ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). However, there did not appear to be a consistent relationship between the alleles related with *AMICA1* and *MPZL3* gene expression and those with lung adenocarcinoma ([Figure 2](#F2){ref-type="fig"}, [Supplementary Table 9](#SD1){ref-type="supplementary-material"}), suggesting that expression of these genes alone is unlikely to mediate this association.

At 9p21.3 we identified rs885518 that appeared to be associated with lung adenocarcinoma (OR=1.17, 95% CI 1.11--1.23, p=6.8×10^−10^). 9p21.3 is a region containing *CDNK2A* and variants associated with multiple cancer types, including lung cancer. Nevertheless, rs885518 is located approximately 200kb centromeric the previously described variants ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}) and shows little evidence for LD (all pairwise r^2^\< 0.01) with rs1333040, a variant previously associated with lung squamous cell carcinoma^[@R3]^ and rs62560775, another variant suggested to be associated with lung adenocarcinoma^[@R25]^ that we confirm to genome significance here. Intriguingly, these variants appear to confer predominant associations with different lung cancer histologies suggesting that they are independent associations ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}).

Aside from the clear smoking-related effects on lung cancer risk through the *CHRNA5* and *CYP2A6* regions and association with *CHRNA2* noted above, the rest of variants we have identified do not appear to clearly influence smoking behaviors ([Table 2](#T2){ref-type="table"}), implying that these associations are likely mediated by other mechanisms. Nevertheless, there is shared genetic architecture between smoking behavior and lung cancer risk, consistent with the notion that genetic variants do influence lung cancer risk also through behavioral mechanisms ([Supplementary Figure 8](#SD1){ref-type="supplementary-material"}).

In conclusion, the genetic susceptibility alleles we describe here explain approximately 12.3% of the familial relative risk previously reported in family cancer databases^[@R26],[@R27]^, out of which 3.5% was accounted for by the novel loci. Our findings emphasize striking heterogeneity across histological subtypes of lung cancer. We expect that further exploration of the related target genes of these susceptibility loci, as well as validation and identification of new loci, will continue to provide insights into the etiology of lung cancer.

Online methods {#S1}
==============

This work is conducted based on the collaboration of Transdisciplinary Research of Cancer in Lung of the International Lung Cancer Consortium (TRICL-ILCCO) and the Lung Cancer Cohort Consortium (LC3). The participating studies are individually described in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

OncoArray genotyping {#S2}
--------------------

Genotyping was completed at the Center for Inherited Disease Research (CIDR), the Beijing Genome Institute, the HelmholtzCenter Munich (HMGU), Copenhagen University Hospital, and the University of Cambridge. Quality control steps follow the approach described previously for the OncoArray^[@R5]^ ([Supplementary Note](#SD1){ref-type="supplementary-material"}).

Genotype quality control {#S3}
------------------------

After removing the 1,193 expected duplicates, QC procedures for the 43,398 individuals are summarized in [Supplementary Note Figure 1](#SD1){ref-type="supplementary-material"}. Standard quality control procedures (detailed in the [Supplementary Note](#SD1){ref-type="supplementary-material"}) were used to exclude underperforming individuals (number of DNAs=1,708) and genotyping assays (judged by success rate, genotype distributions deviated from that expected by Hardy Weinberg equilibrium, number of variants=16,149). After filtering, there were 517,482 SNPs available for analysis.

Identity by Descent (IBD) was calculated between each pair of samples in the data using PLINK to detect unexpected duplicates and relatedness. Details are described in [Supplementary Note](#SD1){ref-type="supplementary-material"}. 340 unexpected duplicated samples (proportion IBD\>0.95) and 940 individuals were removed as related samples with proportion IBD between 0.45 and 0.95. Of these, 721 of them were expected first degree relatives. In total, 0.56% of the total samples were removed as unexpected duplicates or relatives in the QC analysis. We additionally considered the potential that more distant familial relationships could have impacted the results. However, further restriction to proportion IBD \> 0.2 identified 139 second degree relatives and excluding these had minimal impact on the association results ([Supplementary Note Table 1](#SD1){ref-type="supplementary-material"}).

Complete genotype data for X chromosomes were used to verify reported sex by using PLINK sex inference and a support vector machine procedure resulting in 306 non-concordant samples being removed ([Supplementary Note](#SD1){ref-type="supplementary-material"}).

We used the program FastPop (<http://sourceforge.net/projects/fastpop/>)^[@R28]^ was used to identify 5,406 individuals of non-European ancestry ([Supplementary Note](#SD1){ref-type="supplementary-material"}) resulting in a final association analysis including 14,803 lung cancer cases and 12,262 controls.

We confirmed the fidelity genotyping (directly and imputed) of the OncoArray platform by considering concordance of these genotypes relative to genotypes obtained from analogous genotyping platform ([Supplementary Note](#SD1){ref-type="supplementary-material"}).

Imputation analysis {#S4}
-------------------

A detailed description of the imputation procedures used by the OncoArray consortium and in this Lung Oncoarray project, has been described previously.^[@R5]^ Briefly, the reference Dataset was the 1000 Genomes Project (GP) Phase 3 (Haplotype release date October 2014). The forward alignment of SNPs genotyped on the Oncoarray was confirmed by blasting the sequences used for defining SNPs against the 1000 Genomes. Any ambiguous SNPs were subjected to a frequency comparison to 1000 Genomes variants. Allele frequencies were calculated from a large collection of control samples from Europeans (from 108,000 samples) and Asians (11,000 samples). A difference statistic is calculated by the formula: (\|p1-p2\|- 0.01)^2^/((p1+p2)(2-p1-p2)) where p1 and p2 are the frequencies our dataset and in the 1000 genomes respectively^[@R5]^. A cutoff of 0.008 in Europeans and 0.012 in Asians is needed to pass. SNPs where the frequency would match if the alleles were flipped were excluded from imputation, but not from the association analyses.^[@R5]^ AT/GC SNPs were not present in previously genotyped lower density arrays. Because all imputation was performed to the same standard all SNPs had the same orientation at the time of imputation. The OncoArray whole genome data were imputed in a two-stage procedure using SHAPEIT to derive phased genotypes, and IMPUTEv2^[@R29]^ to perform imputation of the phased data. We included for imputation only the more common variant if more than one variant yielded a match at the same position. The detailed parameter settings are in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

Meta-analysis of lung cancer GWAS {#S5}
---------------------------------

FlashPCA^[@R30]^ was run for principal component analysis (PCA) to infer genetic ancestry by genotype. The regression model assumed an additive genetic model and included the first three eigenvalues from FlashPCA as covariates. For imputed data of smaller sample size, which was enrolled in our analysis later, we changed the method score to EM algorithm to accommodate smaller sample size.

We combined imputed genotypes from 14,803 cases and 12,262 controls from the OncoArray series with 14,436 cases and 44,188 controls samples undertaken by the previous lung cancer GWAS^[@R3],[@R4],[@R6]^, including studies of IARC, MDACC, SLRI, ICR, Harvard, NCI, Germany and deCODE as described previously^[@R3],[@R4],[@R6]^, and we ensured that there were no overlap between the ATBC, EAGLE and CARET studies included in both the previous GWAS and current OncoArray dataset by comparing the identity tags (IDs) of all study participants.

In addition to lung cancer, analyses by histological strata (adenocarcinoma, squamous cell carcinoma, small cell carcinoma (SCLC) and smoking status (Ever/Never) was assessed where data were available. Results from analyses defined by Ever and Never smoking strata did not identify any novel variants.

We conducted the fixed effects meta-analysis with the inverse variance weighting and random effects meta-analysis from the DerSimonian-Laird method^[@R31]^. All meta-analysis and calculations were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). As the same referent panel was used for all studies, all SNPs showed the same forward alignment profiles. We excluded poorly imputed SNPs defined by imputation quality R^2^ \< 0.3 or Info \< 0.4 for each meta-analysis component and SNPs with a Minor allele frequency (MAF) \>0.01 (except for *CHEK2* rs17879961 and *BRCA2* rs11571833 which we have validated extensively previously^[@R4]^. We generated the index of heterogeneity(I^2^) and P-value of Cochran's Q statistic to assess heterogeneity in meta-analyses and considered only variants with little evidence for heterogeneity in effect between the studies (P-value of Cochran's Q statistic \>0.05). SNPs were retained for study provided the average imputation R-square was at least 0.4. For SNPs in the 0.4--0.8 range that reached genome wide significance results were evaluated for consistency with neighboring SNPs to assure a reliable inference. Due to the smaller sample size and fewer sites contributing in the strata of Never Smokers and SCLC, we additionally required variants to be present in each of the meta-analysis components to be retained for these 2 stratified analyses.

Conditional analysis was undertaken using SNPTEST where individual level data was available and GCTA^[@R32]^ packages for the previous lung cancer GWAS, with the LD estimates obtained from individuals of European origin for the later. Results were combined using fixed effects inverse variance weighted meta-analysis as described above^[@R33]^.

Assessing Statistical Significance {#S6}
----------------------------------

Genome wide statistical significance was considered at P-values of 5 × 10^−8^ or lower, but we also presented significance per alternative criteria following Bonferroni correction for the number of effective tests or Bayesian False Discovery Probability (BFDP) described below.

To evaluate the effective number of tests we used the Li and Ji (2005)^[@R33]^ method which performs an initial step of filtering out SNPs with MAF\<0.01 (imputation is less reliable for these and power is also limited for most odds ratios). Among the 4,751,148 markers with that MAF there were 1,182,363 effective tests.

The BFDP combines significance level, study power, and cost of false discovery and non-discovery into consideration. The detailed procedures of this method are described in Wakefield, 2007^[@R34]^. Essentially, the approximate Bayes Factor (ABF) which BFDP uses reflects how much the prior odds change in the light of the observed data (i.e. relative probability of the observed estimates under the null versus alternative hypothesis). Given the nature of GWA studies, we applied a flat prior for all variants at prior probability of 10^−6^ and 10^−8^ to demonstrate the range of BFDP.

Annotation of susceptibility loci {#S7}
---------------------------------

We combined multiple sources of *in silico* functional annotation from public databases to help identify potential functional SNPs and target genes, based on previous observations that cancer susceptibility alleles are enriched in *cis*-regulatory elements and alter transcriptional activity. The details are described in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

eQTL analysis of lung cancer sentinel variants {#S8}
----------------------------------------------

To investigate the association between the sentinel variants and mRNA expression, we used three different eQTL datasets: (i) Microarray eQTL study: The lung tissues for eQTL analyses were from patients who underwent lung surgery at three academic sites, Laval University, University of British Columbia (UBC), and University of Groningen. Whole-genome gene expression profiling in the lung was performed on a custom Affymetrix array (GPL10379). Microarray pre-processing and quality controls were described previously. Genotyping was carried on the Illumina Human 1M-Duo BeadChip array. Genotypes and gene expression levels were available for 409, 287 and 342 patients at Laval, UBC, and Groningen, respectively. (ii) NCI RNAseq eQTL study: RNA was extracted from lung tissue samples within the Environment and Genetics in Lung cancer Etiology (EAGLE) study. RNAseq was carried out on 90 lung tissue sampled from an area distant from the tumor (defined here as "non-malignant lung tissue") to minimize the potential for local cancer field effects. Transcriptome sequencing of 90 non-tumor samples was performed on the Illumina HiSeq2000/2500 platform with 100-bp paired-end reads. Genotyping was undertaken using Illumina bead arrays as described previously. (iii) GTEx: eQTL summary statistics based on RNAseq analysis were obtained for eQTL summary statistics from the GTEx data portal <http://www.gtexportal.org/home/>^[@R35]^. This data included 278 individuals with data from lung tissue. Details of these three eQTL studies are included in the [Supplementary Note](#SD1){ref-type="supplementary-material"}.

The Microarray eQTL study was used as a discovery cohort. Probe sets located within 1 Mb up and downstream of lung cancer SNPs were considered for cis-eQTL analyses. We have also explored a 5 Mb interval for lung cancer-associated SNPs not acting as lung eQTL within the 1 Mb window. The top eQTL association for that sentinel variant (or if contained multiple eQTL's with P-value\<0.0005 each was considered), this particular eQTL was then chosen and assessed specifically in the independent NCI and GTEx RNAseq eQTL datasets. Statistical significance was defined the eQTL surpassed a locus specific Bonferroni correlation in the discovery cohort (P-value=0.05/number of probes at that locus) and subsequently there was evidence for replication of the eQTL effect with that variant and gene within the validation cohorts (NCI/GTEx RNAseq).

Lung cancer susceptibility variants in other phenotypes {#S9}
-------------------------------------------------------

We assessed associations between sentinel genetic variant associated with lung cancer and other phenotypes, including smoking behavior Fagerstrӧm Test for Nicotine Dependence, lung function and telomere length. Additional details of these analyses for other phenotypes are described in [Supplementary Note](#SD1){ref-type="supplementary-material"}. Briefly:

### Smoking behaviors {#S10}

The effects of lung cancer sentinel variants and smoking behavior were assessed based on the meta-analysis across 3 studies: ever-smoking controls with intensity information from the Oncoarray studies (N=8,120), deCODE (N=40,882) and UK Biobank (N=42,044). The association with nicotine dependence was evaluated based on Fagerstrӧm Test for Nicotine Dependence (FTND) data collected in 4 studies (n=17,074): deCODE Genetics, Environment and Genetics in Lung Cancer Etiology (EAGLE), Collaborative Genetic Study of Nicotine Dependence (COGEND), and Study of Addiction: Genetics and Environment (SAGE) and among current smokers in one other study \[Chronic Obstructive Pulmonary Disease Gene (COPDGene). The study-specific SNP association results were combined using fixed effects, inverse variance-weighted meta-analysis with genomic control applied. Specifically, for the 8p21 variant rs11780471, we additionally considered other aspects of smoking behavior data from UKBiobank, deCODE and OncoArray controls. We additionally included summary statistics for the rs11780471 variants from the TAG consortium (described in detail in the [Supplementary Note](#SD1){ref-type="supplementary-material"}).

### Lung function {#S11}

The lung function *in silico* look up was conducted in SpiroMeta consortium, which included 38,199 European ancestry individuals. The genome-wide associations between genetic variants and forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC with 1000 Genomes Project (phase 1)-imputed genotypes in the GWAS with 38,199 individuals^[@R36]^.

### Telomere Length (TL) {#S12}

Sentinel genetic variants associated with telomere length were those described by Codd et al^[@R22]^. Telomere lengths in 6,766 individuals from the UK Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) study controls using a real-time PCR methodology and genotyping as described in Pooley et al., 2013^[@R37]^.

Genetic heritability and correlations {#S13}
-------------------------------------

Genome-wide SNP heritability and correlation estimates were obtained using association summary statistics and linkage disequilibrium (LD) information through LD Score (LDSC) regression analyses^[@R38],[@R39]^. These analyses were restricted to HapMap3 SNPs with minor allele frequency above 5% in European populations of 1000 Genomes. Association summary statistics used for these analyses were based on lung cancer histological/smoking types (lung cancer overall, adenocarcinoma, squamous cell, small cell, ever smokers and never smokers) and smoking behavior parameters (cigarettes per day (CPD), smoking status (ever vs never smokers), and smoking cessation (current vs former smokers) from TRICL-ILCCO OncoArray consortium and Tobacco And Genetics consortium (<https://www.med.unc.edu/pgc/downloads>)^[@R40]^.

Estimating the percentage of familial relative risks explained {#S14}
--------------------------------------------------------------

The familial relative risk to a first degree relative accounted for by an individual variant (denoted as λ~i~) is estimated based on relative risk per allele and allele frequency for that variant, using the method described in Hemminki et al^[@R41],^ and Bahcall^[@R42]^, under the assumption of log-additive effect. Assuming the effects of all susceptibility variants combined multiplicatively and not in linkage disequilibrium, the combined effect (λ~T~) can then be expressed as the product of all λ~i~. The proportion of the familial relative risk attributable to the totality of the susceptibility variants can then be computed as log(λ~T~)/log(λ~P~). For lung cancer, the λ~P~ is approximately 2.0 based on the family cancer databases^[@R26],[@R27]^. The percentage reported is based on the 18 sentinel variants reported in [Table 2](#T2){ref-type="table"}. The multiple independent alleles in the same locus are not accounted for in this estimation.
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Genetic sharing analysis: RCT, SLi, XiJ, JDM, RJH

**Data Availability**

The datasets generated during the current study are available at the URL: <https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001273.v1.p1>. Prior meta-analyses of genome-wide association studies contributing to this study are available at <https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000876.v1.p1>.

The Oncoarray data deposited at dbGAP includes data excluded from the analyses presented in this paper to avoid overlap with prior studies. Readers interested in obtaining a copy of the original data can do so by completing a proposal request form that is located at <http://oncoarray.dartmouth.edu>)

Cluster plots of all SNPs on the Oncoarray are located at <http://oncoarray.dartmouth.edu>

**URLs**

OncoArray: <http://epi.grants.cancer.gov/oncoarray/>)

<http://oncoarray.dartmouth.edu>)

Fastpop <http://sourceforge.net/projects/fastpop/>)

PLINK: <http://zzz.bwh.harvard.edu/plink/>)

IMPUTE2: <http://mathgen.stats.ox.ac.uk/impute/impute_v2.html>)

SHAPEIN: <https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html>)

GTEx: <http://www.gtexportal.org/home/>)

BRAINEAC: <http://braineac.org>)

TAG: <https://www.med.unc.edu/pgc/downloads>

![Manhattan plots of lung cancer risk overall and by histological subtypes\
(a) lung cancer risk overall, 29,266 cases and 56,450 controls (b) adenocarcinoma, 11,273 cases and 55,483 controls (c) squamous cell carcinoma 7,426 cases and 55,627 controls. Each locus is annotated by their cytoband locations. The X‐axis represents chromosomal locations and the Y‐axis represents −log10(P‐value). Black denotes the previously known loci and Red denotes the new loci identified in this analysis](nihms875731f1){#F1}

![Scatter plots comparing variants across the 6q27, 15q21.1, 8p12 and 11q23.3 susceptibility loci and (Y-axis) their associated with lung cancer (or lung adenocarcinoma, as relevant) and (X-axis) the lung cis--eQTL (GTEx)\
Each variant (dot) is colored relative the degree of linkage disequilibrium (r^2^) with sentinel lung cancer variant (marked) at that locus. Indented table, association between sentinel variant and lung cancer (or histological subtype) as well as the eQTL evidence in lung epithelium for the microarray (Laval, UBC, Groningen) and RNAseq (NCI and GTEx) cohorts. At 6q27, 15q21.1 and 8p12, the variants associated with lung cancer also tend to be those that that are lung cis-eQTL's for *RNASET2*, *SECISBP2L* and *NRG1*, respectively. At 11q23.3, while the sentinel variant (rs1056562) is a lung cis-eQTL for *AMICA1*, additional variants are *AMICA1* lung cis-eQTL's, but not associated with lung adenocarcinoma and *vice versa* suggesting an alternate candidate gene may be responsible for this association or a pleiotropic effect at this locus.](nihms875731f2){#F2}

![eQTL and smoking behavior analysis of the 8p21 lung cancer susceptibility locus. Upper panel\
Scatter plots of variants across the 8p21 locus and their associated with lung cancer (Y-axis) and *CHRNA2* eQTL (X-axis) in lung epithelial tissues (panel a) and *CHRNA2* eQTL in brain cerebellum tissues (panel b). **Panel C.** eQTL association between rs11780471 across tissues from different parts of the brain from GTEx and Braineac consortia noting *CHRNA2* cis- eQTL effect appears restricted to the brain cerebellum. **Panel D.** Association between rs11780471 and smoking phenotypes, noting evidence for association between smoking status (ever vs never) and age of initiation, with lung cancer risk allele carriers (G) more likely to be ever smokers and take up smoking earlier. Fagerström Test for Nicotine Dependence (FTND) index, error bars indicate the 95% confidence intervals.](nihms875731f3){#F3}

###### 

Demographic characteristics of the participating studies after quality control filters

                                                          Lung cancer patients   Controls                                               
  ------------------------------------------------------- ---------------------- ---------- ------------------------------------------- --------
  OncoArray studies- passed QC                            14803                  *(51)*     12262                                       *(22)*
  Published GWAS studies[a](#TFN1){ref-type="table-fn"}   14463                  *(49)*     44188                                       *(78)*
                                                                                                                                        
  **Total**                                               **29266**                         **56450**                                   
                                                                                                                                        
  Age                                                                                                                                   
   \<=50                                                    3112                 *(12)*       6032                                      *(12)*
   \>50                                                   23025                  *(88)*     44075                                       *(88)*
  Sex                                                                                                                                   
   Male                                                   18208                  *(62)*     27178                                       *(53)*
   Female                                                 11059                  *(38)*     24069                                       *(47)*
  Smoking status                                                                                                                        
   Never                                                    2355                   *(9)*      7504                                      *(31)*
   Ever                                                   23223                  *(91)*     16964                                       *(69)*
   Former                                                   9037                 *(35)*       8554                                      *(35)*
   Current                                                13356                  *(52)*       7477                                      *(31)*
  Histology [c](#TFN3){ref-type="table-fn"}                                                                                             
   Adenocarcinoma                                         11273                  *(39)*         55483 [b](#TFN2){ref-type="table-fn"}   
   Squamous cell carcinoma                                  7426                 *(25)*         55627 [b](#TFN2){ref-type="table-fn"}   
   Small cell carcinoma                                     2664                   *(9)*        21444 [b](#TFN2){ref-type="table-fn"}   

Previous GWAS studies include IARC, MDACC, SLRI, ICR, Harvard, ATBC, CPSII, German and deCODE studies.

Number of non-cancer individuals included in the corresponding histology-specific analysis.

The remaining 27% includes other histological subsets, such as large cell carcinoma, non-small cell lung cancer, NOS, mixed histology, and unknown.

###### 

The association between sentinel variants representing each lung cancer locus and lung cancer risk.

  Strata   Locus[\*](#TFN4){ref-type="table-fn"}      rs number     Gene          Allele^a^   Imputed versus Oncoarray genotyped   Candidate Oncoarray   EAF     OR    95%CI        P-value    CPD           FTND          FEV1          FVC           FEV1/FVC
  -------- ------------------------------------------ ------------- ------------- ----------- ------------------------------------ --------------------- ------- ----- ------------ ---------- ------------- ------------- ------------- ------------- -------------
  Lung     1p31.1[\*](#TFN4){ref-type="table-fn"}     rs71658797    *FUBP1*       T_A         Oncoarray                            *No*                  0.103   1.1   1.09--1.18   3.3E-11    0.056         0.334         0.445         0.898         0.334
  Lung     6q27[\*](#TFN4){ref-type="table-fn"}       rs6920364     *RNASET2*     G_C         Imputed                              *eQTL*                0.456   1.1   1.05--1.10   1.3E-08    0.833         0.104         0.927         0.876         0.986
  Lung     8p21.1[\*](#TFN4){ref-type="table-fn"}     rs11780471    *CHRNA2*      G_A         Imputed                              *Lung*                0.060   0.9   0.83--0.91   1.7E-08    0.646         0.403         **6.9E-04**   0.055         **0.016**
  Lung     13q13.1                                    rs11571833    *BRCA2*       A_T         Imputed                              *Lung*                0.011   1.6   1.43--1.80   6.1E-16    0.890         0.312         0.601         0.667         0.237
  Lung     15q21.1[\*](#TFN4){ref-type="table-fn"}    rs66759488    *SEMA6D*      G_A         imputed                              *Lung*                0.362   1.1   1.05--1.10   2.8E-08    0.266         0.888         0.739         0.200         0.202
  Lung     15q25.1                                    rs55781567    *CHRNA5*      C_G         Imputed                              *Lung*                0.367   1.3   1.27--1.33   3.1E-103   **6.8E-38**   **9.7E-16**   **7.2E-03**   **0.020**     0.144
  Lung     19q13.2[ˆ](#TFN6){ref-type="table-fn"}     rs56113850    *CYP2A6*      C_T         Oncoarray                            *Lung*                0.440   0.9   0.86--0.91   5.0E-19    **8.1E-20**   **7.5E-04**   0.822         0.826         0.319
  Adeno    3q28                                       rs13080835    *TP63*        G_T         Imputed                              *Lung*                0.493   0.9   0.87--0.92   7.5E-12    0.803         0.336         0.135         0.445         0.834
  Adeno    5p15.33                                    rs7705526     *TERT*        C_A         Oncoarray                            *All*                 0.342   1.3   1.21--1.29   3.8E-35    0.511         0.738         0.292         **0.038**     0.657
  Adeno    8p12[\*](#TFN4){ref-type="table-fn"}       rs4236709     *NRG1*        A_G         Imputed                              *eQTL*                0.218   1.1   1.09--1.18   1.3E-10    0.991         0.957         0.503         0.151         0.403
  Adeno    9p21.3[\*](#TFN4){ref-type="table-fn"}     rs885518      *CDNK2A*      A_G         Imputed                              *Several*             0.101   1.2   1.11--1.23   9.96E-10   0.904         0.321         0.421         0.096         0.146
  Adeno    10q24.3[\*](#TFN4){ref-type="table-fn"}    rs11591710    *OBFC1*       A_C         Imputed                              *Lung*                0.137   1.2   1.11--1.22   6.3E-11    0.500         0.152         **0.027**     **0.019**     0.533
  Adeno    11q23.3[\*](#TFN4){ref-type="table-fn"}    rs1056562     *AMICA1*      C_T         Oncoarray                            *Breast*              0.473   1.1   1.07--1.14   2.8E-10    0.717         0.538         0.449         0.718         **0.039**
  Adeno    15q21.1[\*](#TFN4){ref-type="table-fn"}    rs77468143    *SECISBP2L*   T_G         Imputed                              *No*                  0.253   0.9   0.83--0.89   1.7E-16    0.071         0.184         **4.9E-03**   0.440         **1.4E-03**
  Adeno    20q13.33[\*](#TFN4){ref-type="table-fn"}   rs41309931    *RTEL1*       G_T         Imputed                              *Prost/ColR*          0.117   1.2   1.11--1.23   1.3E-09    0.146         0.939         0.964         0.657         0.284
  SQC      6p21.33                                    rs116822326   *MHC*         A_G         Imputed                              *Lung*                0.155   1.3   1.19--1.32   3.8E-19    0.392         0.774         0.132         0.498         0.103
  SQC      12p13.33                                   rs7953330     *RAD52*       G_C         Oncoarray                            *Lung*                0.315   0.9   0.83--0.90   7.3E-13    0.800         0.463         0.019         **3.3E-03**   0.424
  SQC      22q12.1                                    rs17879961    *CHEK2*       A_G         Oncoarray                            *Lung*                0.005   0.4   0.32--0.52   5.7E-13    0.441         0.360         **0.041**     **0.040**     0.805

denote novel locus identified to GWAS significance by this study; a, reference_effect. Bolded p-values indicate significant associations with consistent direction as expected. Genome positions relative to GRCh37, EAF, effective allele frequency; OR, odds (log additive) ratio; 95%CI, 95% confidence interval. P-value, based on fixed-effect meta-analysis adjusted for age, sex and genetically derived ancestry; CPD, cigarette per day; FTND, Fagerstrӧm Test for Nicotine Dependence; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

Adeno, adenocarcinoma; SQC, squamous cell carcinoma.

marker had an acceptable, but not ideal concordance rate (see [Supplementary Note](#SD1){ref-type="supplementary-material"})
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